Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized (Q40225686)
Jump to navigation
Jump to search
scientific article published on January 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized |
scientific article published on January 2014 |
Statements
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase III trial (English)
Pierfrancesco Tassone
Pierosandro Tagliaferri
Maria S Rotundo
Raffaele Conca
Antonella Licchetta
Pierpaolo Pastina
Elena Bestoso
Antonella Fioravanti
Giacomo M Guidelli
Maria T Bianco
Elodia Martino
Enrico Mini
Giovanni Mantovani
Ruggero Ridolfi